Company intelligence / Profile preview
Vyriad
Rochester, Minnesota, United Statesvyriad.com ↗
- Ownership
- Private
- Employees
- ~90
- Development stage
- Phase 2
01
Overview
Phase 1-2 trials with oncolytic viruses are underway in multiple cancer indications, both as monotherapies and in combination with immuno-oncology drugs. The company has administered oncolytic virotherapies to over 300 patients at over 40 clinical sites in the USA and Brazil.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virotherapyIn vivo gene therapyGene editingIn vivo CAR-T cell therapy
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Beyond the preview
Go deeper on Vyriad.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vyriad.